<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04258982</url>
  </required_header>
  <id_info>
    <org_study_id>GIRH-201927</org_study_id>
    <nct_id>NCT04258982</nct_id>
  </id_info>
  <brief_title>The Copmparison of Accuracy of PtcCO2 and in PetCO2 in COPD Patients With NIV Treatment</brief_title>
  <official_title>The Copmparison of Accuracy of PtcCO2 and in PetCO2 in COPD Patients With NIV Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhenfeng He</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The chronic obstructive pulmonary disease (COPD) patients with type II respiratory failure
      always needs PaCO2 test to monitor the changes of disease. Method used mostly nowadays to
      detect PaCO2 is arterial puncture which is accurate but is invasive, painful and non-dynamic.
      Noninvasive measurement methods includes end-tidal CO2 (PetCO2), transcutaneous CO2 (PtcCO2)
      which can monitor the PaCO2 dynamically and noninvasively, but their accuracy is in
      controversy. Common PetCO2 is especially inaccurate in COPD patients while our team find that
      the accuracy can be improved by prolong expiration method (PetCO2 (P)).So the investigators
      want to compare the accuracy of PtcCO2 and PetCO2(P) in AECOPD patients during noninvasive
      ventilation(NIV).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>partial arterial pressure of end-tidal CO2 measured by prolong expiration method [PetCO2(P)]</measure>
    <time_frame>2 hours</time_frame>
    <description>PetCO2(P) will be measured before and after NIV treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>partial arterial pressure of transcutaneous CO2 (PtcCO2)</measure>
    <time_frame>2 hours</time_frame>
    <description>PtcCO2 will be measured before and after NIV treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>partial arterial pressure of carbon dioxide (PaCO2)</measure>
    <time_frame>2 hours</time_frame>
    <description>PaCO2 will be measured before and after NIV treatment.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>AECOPD group</arm_group_label>
    <description>The study incruit AECOPD patients with type II respiratory failure who need the NIV treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention</description>
    <arm_group_label>AECOPD group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        AECOPD patients with type II respiratory failure who need NIV treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AECOPD patients with type II respiratory failure who need NIV treatment

        Exclusion Criteria:

          -  hemodynamics is unstable;

          -  any other lung disease despite COPD;

          -  other diseases influencing experiments: Cognitive impairment disease mouth and nose
             trauma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shanshan Zha, master</last_name>
    <phone>15013023031</phone>
    <email>zhass2011@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University.</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenfeng He, MD</last_name>
      <phone>8602083062882</phone>
      <email>zfHe_2019@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 2, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Zhenfeng He</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

